Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEACON 2 for relapsed neuroblastoma
NL-OMON60508Phase 2Not yet recruiting
- Sponsor
- University of Birmingham
- Start
- Jun 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of temozolomide, irinotecan, Dinutuximab beta and bevacizumab in neuroblastoma (4 arms), sponsored by University of Birmingham. Primary endpoints: Progression-free survival and Safe and tolerable combination regimen. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
temozolomideirinotecanDinutuximab betabevacizumab
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NL-OMON60508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60508.